Allan Bradley, PhD is a Professor in the Cambridge Institute of Therapeutic Immunology and Infectious Disease atUniversity of Cambridge. Professor Bradley received his BA, MA & PhD in Genetics from the University of Cambridge where his graduate and postdoctoral research laid the foundation for making genetically altered mice. This pioneering work on embryonic stem cells contributed to the Nobel Prize awarded to his advisor Martin Evans for ES cell technology. In 1987, Dr Bradley established an independent laboratory at Baylor College of Medicine, Houston Texas, USA and was he was appointed as a Howard Hughes Medical Institute Investigator. His laboratory at Baylor played a seminal role in developing the techniques, technology and tools for genetic manipulation in the mouse, generating andanalyzing many of the first generation of mouse knockouts as well as established chromosome engineering technology.
In 2000, Professor Bradley returned to the UK to take up a leadership role as Director of the Wellcome Trust Sanger Institute, one of Europe’s premier research Institutions, famous for its contribution to the human genome project. During his 10-year term he established a new mission for the Institute, transforming it into an academic genome centre focused on genetic analysis of gene function. His laboratory remained active during his tenure and his team returnedto the University of Cambridge in 2018. Professor Bradley has authored more than 350 primary research papers, he has mentored a cadre of young scientists on both sides of the Atlantic, many of whom now occupy leadership roles in universities and medical schools in the USA, Europe and Asia. In 2002 he was honored with the highest award in British Science by election to the Royal Society. He is also a Fellow of the Academy of Medical Sciences and a member of EMBO.
Professor Bradley is a serial entrepreneur, in 1995 he established Lexicon Genetics to industrialize mouse knockoutsfor drug-target discovery. Lexicon Genetics was floated on the NASDQ five years later. In 2000 he founded Spectral Genomics which developed micro-arrays for diagnosis of human disorders which was eventually sold to Perkin Elmer Inc. In 2010 he founded Kymab Limited, serving as Director for the life of the company and the CSO from 2012.Kymab successfully engineered the most advanced mouse platform for discovery of human therapeutic antibodies,pioneered and applied single cell sequencing to B cells for antibody discovery and advanced several antibodies into clinical development. Kymab was recently acquired by Sanofi for $1.45bn. In 2019, he founded PetMedix Ltd, where he served as the CSO & Director. PetMedix develops therapeutic antibodies for dogs and cats. In 2022, he founded T-Therapeutics Ltd, where he serves as the CSO and Director.